More importantly, FGF19 signaling through the FGFR4/β-klotho receptor complex has been shown to be a key driver of growth and survival in hepatocellular carcinoma, which makes selective FGFR4 inhibition an attractive therapeutic opportunity. Here, FGF19 is linked to hepatocellular carcinoma.